InChI=1S/C9H11N3O4/c10-5-1-2-12-8-7(16-9(12)11-5)6(14)4(3-13)15-8/h1-2,4,6-8,10,13-14H,3H2/t4-,6-,7+,8-/m1/s1 |
BBDAGFIXKZCXAH-CCXZUQQUSA-N |
OC[C@H]1O[C@@H]2[C@@H](Oc3nc(=N)ccn23)[C@@H]1O |
|
antimetabolite
A substance which is structurally similar to a metabolite but which competes with it or replaces it, and so prevents or reduces its normal utilization.
|
|
prodrug
A compound that, on administration, must undergo chemical conversion by metabolic processes before becoming the pharmacologically active drug for which it is a prodrug.
antineoplastic agent
A substance that inhibits or prevents the proliferation of neoplasms.
|
|
View more via ChEBI Ontology
(2R,3R,3aS,9aR)-2-(hydroxymethyl)-6-imino-2,3,3a,9a-tetrahydro-6H-furo[2',3':4,5][1,3]oxazolo[3,2-a]pyrimidin-3-ol
|
ancitabina
|
ChemIDplus
|
ancitabine
|
ChemIDplus
|
ancitabine
|
WHO MedNet
|
ancitabinum
|
ChemIDplus
|
2,2'-anhydro-1-(β-D-arabinofuranosyl)cytosine
|
ChEBI
|
2,2'-anhydro-AraC
|
ChEBI
|
2,2'-anhydroarabinosylcytosine
|
ChemIDplus
|
2,2'-anhydrocytidine
|
ChemIDplus
|
2,2'-cyclocytidine
|
ChemIDplus
|
2,2'-O-cyclocytidine
|
ChemIDplus
|
[2R-(2α,3β,3aβ,9aβ)]-2,3,3a,9a-tetrahydro-3-hydroxy-6-imino-6H-furo[2',3':4,5]pxazolo[3,2-a]pyrimidine-2-methanol
|
ChEBI
|
anhydrocytidine
|
ChemIDplus
|
cyclocytidine
|
ChEBI
|
O2,2'-cyclocytidine
|
ChEBI
|
31698-14-3
|
CAS Registry Number
|
ChemIDplus
|
669322
|
Reaxys Registry Number
|
Reaxys
|
6204036
|
PubMed citation
|
Europe PMC
|
6206222
|
PubMed citation
|
Europe PMC
|
77191
|
PubMed citation
|
Europe PMC
|
|